Semaphar SRL
The score of Semaphar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -55 % Total assets +17 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Semaphar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 101,958 € | ||||
| Equity | 198,182 € | ||||
| Cash | 135,593 € | ||||
| EBITDA | 153,403 € | ||||
| Total assets | 579,404 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 09 Mar 2026
- Year ended 31 Dec 2024filed on 05 Jun 2025
- Year ended 31 Dec 2023filed on 21 May 2024
- Year ended 31 Dec 2022filed on 15 May 2023
- Year ended 31 Dec 2021filed on 10 May 2022
Semaphar's financial analysis
- Solvency34.2%sector median: 58.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Semaphar
Semaphar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0568.568.963
- VAT number
- BE0568568963
- Peppol
- Registered · 0208:0568568963 · as of 09 Nov 2026
- Legal form
- SRL
- Incorporated
- 09 Jan 2015
- Registered office
- 1370 Jodoigne
- Latest accounts
- 2025 · filed on 09 Mar 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Semaphar (SRL) has been based in Jodoigne since 2015, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 101,958 € and equity of 198,182 €; its revenue is not published. Its solvency stands at 34.2%, below the median of its sector (58.2%).
Companies similar to Semaphar
Companies in the same business, of comparable size and area, outside its group.
- CTTec Research and experimental development on natural sciences and engineering Menen · balance sheet 259,750 €
- Huisarts Nadine Costers Research and experimental development on natural sciences and engineering Knokke-Heist · balance sheet 502,719 €
- Belma Technologies Research and experimental development on natural sciences and engineering Liège · balance sheet 281,040 €
- TRACKS&Co Research and experimental development on natural sciences and engineering Jurbise · balance sheet 528,835 €
- PFx Biotech Research and experimental development on natural sciences and engineering Ghent · balance sheet 593,378 €
- MDTrials Research and experimental development on natural sciences and engineering Bruges · balance sheet 372,427 €
- Certor Research and experimental development on natural sciences and engineering Mechelen · balance sheet 505,224 €
- NasaPharm Research and experimental development on natural sciences and engineering Blegny · balance sheet 606,267 €
Frequently asked questions about Semaphar
What is the revenue of Semaphar?
Semaphar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Semaphar?
In Belgium, the VAT number is the company number prefixed with BE: BE0568568963 for Semaphar, if the company is VAT-registered. Its company number (CBE) is 0568.568.963.
Where is the registered office of Semaphar?
According to the CBE register, the registered office of Semaphar is in 1370 Jodoigne.
What is the equity of Semaphar?
At the close of the 2025 financial year, the equity of Semaphar amounts to 198,182 €, a solvency of 34.2% of total assets.
Who manages Semaphar?
The register lists 1 active mandates at Semaphar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Semaphar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →